P M Goggin
Overview
Explore the profile of P M Goggin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
544
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Goggin P, Zygalakis K, Oreffo R, Schneider P
Eur Cell Mater
. 2016 May;
31:264-95.
PMID: 27209400
Osteocytes are involved in mechanosensation and mechanotransduction in bone and hence, are key to bone adaptation in response to development, ageing and disease. Thus, detailed knowledge of the three-dimensional (3D)...
2.
Gordon J, Prothero J, Thornton C, Pickard K, di Sabatino A, Goggin P, et al.
J Crohns Colitis
. 2010 Dec;
3(3):175-82.
PMID: 21172267
Background: Thalidomide, one of whose activities is to inhibit Tumour Necrosis Factor (TNF)-α production, has been reported to be an effective treatment for refractory inflammatory bowel disease (IBD). TNF-α driven...
3.
Gordon J, Green S, Goggin P
QJM
. 2005 Oct;
98(11):779-88.
PMID: 16214835
Cancer cachexia is a severe debilitating disorder for which there are currently few therapeutic options. It is driven by the release of pro-inflammatory cytokines and cachectic factors by both host...
4.
Gordon J, Trebble T, Ellis R, Duncan H, Johns T, Goggin P
Gut
. 2005 Mar;
54(4):540-5.
PMID: 15753541
Background: Proinflammatory cytokines, especially tumour necrosis factor alpha (TNF-alpha), play a prominent role in the pathogenesis of cancer cachexia. Thalidomide, which is an inhibitor of TNF-alpha synthesis, may represent a...
5.
Gordon J, Goggin P
Postgrad Med J
. 2003 Apr;
79(929):127-32.
PMID: 12697909
Forty years on from its worldwide withdrawal, thalidomide is currently undergoing a remarkable renaissance as a novel and powerful immunomodulatory agent. Over the last decade it has been found to...
6.
Pearce C, Collett J, Goggin P, Duncan H
Clin Nutr
. 2001 Sep;
20(5):461-4.
PMID: 11534943
We describe two cases in which self-propelling, blind placed nasojejunal tubes were placed in severe hyperemesis gravidarum. This method provides an alternative to parenteral nutrition and to percutaneous endoscopic tubes,...
7.
Pearce C, Martin H, Duncan H, Goggin P, Poller D
Arch Pathol Lab Med
. 2001 Jul;
125(8):1110-2.
PMID: 11473472
We describe the case of a patient with Rett syndrome, a syndrome characterized by progressive infant encephalopathy, developmental delay, dementia, autism, ataxia, microcephaly, spastic paraparesis, and autonomic neuropathy with constipation....
8.
Pearce C, Goggin P, Collett J, Smith L, Duncan H
Clin Nutr
. 2000 Jun;
19(2):133-5.
PMID: 10867732
Background And Aims: The standard method of removing percutaneous endoscopic gastrostomy tubes is by gastroscopy. This has implications for endoscopy time and resources, and we believe is not always necessary....
9.
Roseveare C, Patel P, Simmonds N, Goggin P, Kimble J, Shepherd H
Eur J Gastroenterol Hepatol
. 1998 Sep;
10(8):653-7.
PMID: 9744693
Objective: To compare modified Gianturco metal stents with plastic Atkinson tubes in the palliation of malignant dysphagia. Design: Patient single-blind, multi-centre prospective, randomized trial. Setting: Three district general hospitals in...
10.
Fall C, Goggin P, Hawtin P, Fine D, Duggleby S
Arch Dis Child
. 1997 Dec;
77(4):310-4.
PMID: 9389233
Aim: To examine childhood correlates of Helicobacter pylori infection in adults. Design: Follow up study of men and women whose birth weight, weight at age 1 year, and feeding in...